Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493843 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 501
- Enrollment target
NCT01493843 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 501 participants.
The verdict
NCT01493843, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 501 participants
- Enrollment target
Study Summary
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous NSCLC) bevacizumab (B). Anticipated time on study treatment is until disease progression or intolerable toxicity occurs. Participants in placebo arms with disease progression may cross over to open-label active pictilisib.
Interventions
- DRUG Placebo
- DRUG carboplatin
- DRUG bevacizumab
- DRUG paclitaxel
- DRUG pictilisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2012-01-20 |
| Est. Completion | 2016-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493843
The ClinicalTrials.gov registry entry for NCT01493843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01493843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01493843 about?
NCT01493843 is a clinical study titled "Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer". This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). P...
What is the current status of trial NCT01493843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 501 participants. The study started on 2012-01-20. Estimated completion is 2016-03-30.
What interventions are being tested in trial NCT01493843?
The interventions under investigation include: Placebo (DRUG), carboplatin (DRUG), bevacizumab (DRUG), paclitaxel (DRUG), pictilisib (DRUG).
Who is sponsoring clinical trial NCT01493843?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.